首页|期刊导航|山西医科大学学报|瑞香素增强肺癌细胞放疗敏感性的机制研究

瑞香素增强肺癌细胞放疗敏感性的机制研究OA

Mechanism of Daphnetin enhancing radiotherapy sensitivity of lung cancer cells

中文摘要英文摘要

目的 探讨瑞香素对Lewis肺癌(Lewis lung cancer,LLC)细胞小鼠移植瘤的放射增敏机制.方法 建立肺癌LLC细胞小鼠移植瘤模型;待移植瘤平均体积增至约80 mm3,且大小均一(为第0天),将24只小鼠随机分为4组:对照组、瑞香素组、照射组以及瑞香素+照射组.分别于第2~6天对瑞香素组和瑞香素+照射组小鼠腹腔注射20 mg/kg的瑞香素,每天1次,共5次;对照组与照射组则注射等量生理盐水.于第6,8,10天,照射组和瑞香素+照射组同步接受3次局部4 Gy的放射线照射.第11天起各组均不再予特殊处理.自第0日起,每隔1天测量1次小鼠肿瘤体积,待对照组小鼠肿瘤体积最大增长至接近1 500 mm3时(第 26天),颈椎脱臼法处死小鼠,测量移植瘤体积,计算肿瘤体积抑制率(抑瘤率);Western blot法检测瘤体细胞内p53、核糖核苷酸还原酶调节亚基M2(RRM2)及细胞周期蛋白(Cyclin D1)蛋白表达水平;免疫荧光法检测Cyclin D1荧光强度.结果 与对照组相比,瑞香素组、照射组及瑞香素+照射组小鼠移植瘤体积均减小(P<0.01).与瑞香素组或照射组相比,瑞香素+照射组瘤体体积减小(P<0.01),抑瘤率明显提高(P<0.01).在蛋白表达方面,与对照组相比,瑞香素组与瑞香素+照射组p53表达明显升高(P<0.001),RRM2和Cyclin D1表达降低(P<0.05),而照射组RRM2和Cyclin D1表达升高(P<0.05).与照射组相比,瑞香素+照射组p53表达明显升高(P<0.001),RRM2与Cyclin D1表达明显降低(P<0.001).免疫荧光方面,与对照组相比,瑞香素组与瑞香素+照射组Cyclin D1荧光强度降低(P<0.01),照射组则明显升高(P<0.001).与照射组相比,瑞香素+照射组Cyclin D1荧光强度明显降低(P<0.001).结论 增敏剂量的瑞香素可增强放疗对肺癌LLC细胞小鼠移植瘤的生长抑制效果,起到放疗增敏作用,可能与其激活p53进而抑制RRM2及Cyclin D1的形成,阻碍肿瘤细胞修复有关.

Objective To investigate the radiosensitizing mechanism of daphnetin on Lewis lung cancer(LLC)cell-induced xeno-grafts in mice.Methods A mouse xenograft model of LLC cells was established.When the average volume of xenografts reached approximately 80 mm³ with uniform size(designated as Day 0),24 mice were randomly divided into four groups:control group,daph-netin group,irradiation group,and daphnetin+irradiation group.At days 2-6,the mice in daphnetin group and daphnetin+irradiation group were intraperitoneally injected with daphnetin at 20 mg/kg once daily for five times,and the mice in control group and irradia-tion group received equal volumes of normal saline.At days 6,8,10,the mice in irradiation group and daphnetin+irradiation group underwent local radiotherapy at 4 Gy per session.No further treatments were administered from day 11 in all groups.Tumor volume was measured every other day from day 0.When the maximum tumor volume in control group reached 1 500 mm³(day 26),all mice were sacrificed by cervical dislocation.Tumor tissues were measured to calculate the tumor volume inhibition rate(TIR).Western blot was performed to detect the protein expression levels of p53,ribonucleotide reductase regulatory subunit M2(RRM2),and Cyclin D1 in tumor cells.Immunofluorescence was used to determine the fluorescence intensity of Cyclin D1.Results Compared with control group,tumor volumes were significantly reduced in daphnetin group,irradiation group,and daphnetin+irradiation group(P<0.01).Compared with daphnetin group and irradiation group,the mice in daphnetin+irradiation group showed a reduction in tumor volume and a increase of tumor volume inhibition rate(P<0.01).Compared with control group,p53 expression was significantly increased in daphnetin group and daphnetin+irradiation group(P<0.001),while the expressions of RRM2 and Cyclin D1 were decreased(P<0.05);and the expression of RRM2 and Cyclin D1 was increased in irradiation group(P<0.05).Compared with irradiation group,p53 expression significantly increased(P<0.001),and RRM2 and Cyclin D1 expressions significantly decreased in daphnetin+irradiation group(P<0.001).Immunofluorescence results showed that,compared with control group,Cyclin D1 fluorescence intensity decreased in daphnetin group and daphnetin+irradiation group(P<0.01),but increased in irradiation group(P<0.001).Cyclin D1 fluorescence intensity in daphnetin+irradiation group was also significantly lower than in irradiation group(P<0.001).Conclusion Daphnetin,at a radiosensitizing dose,can enhance the inhibitory effect of radiotherapy on the growth of LLC xenografts in mice,exerting a radiosen-sitizing effect.This mechanism may be related to the activation of p53,which in turn inhibits the formation of RRM2 and Cyclin D1,thereby hindering tumor cell repair.

孟小双;崔震庭;马建新

徐州医科大学附属连云港市立东方医院放疗科,连云港 222042徐州医科大学附属连云港市立东方医院放疗科,连云港 222042徐州医科大学附属连云港市立东方医院放疗科,连云港 222042

医药卫生

肺癌LLC放疗增敏瑞香素p53RRM2Cyclin D1

lung cancerLewis lung cancerradiosensitizationdaphnetinp53RRM2Cyclin D1

《山西医科大学学报》 2026 (1)

17-22,6

2023年江苏省中医药科技发展项目(MS2023122)

10.13753/j.issn.1007-6611.2026.01.003

评论